BeyondSpring Inc. Ordinary Shares
Veridion Score
Composite trend over time
Why is BYSI moving today?
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BYSI.
BYSI insider activity
BeyondSpring Inc. Ordinary Shares
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for BYSI.
BYSI contract awards, year to date.
Public federal awards linked to this ticker.
BYSI lobbying filings, year to date.
Registered lobbying filings matched to BeyondSpring Inc. Ordinary Shares.